Blood Cancer Journal (May 2023)

UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

  • Julia-Annabell Georgi,
  • Sebastian Stasik,
  • Jan-Niklas Eckardt,
  • Sven Zukunft,
  • Marita Hartwig,
  • Christoph Röllig,
  • Jan Moritz Middeke,
  • Uta Oelschlägel,
  • Utz Krug,
  • Tim Sauer,
  • Sebastian Scholl,
  • Andreas Hochhaus,
  • Tim H. Brümmendorf,
  • Ralph Naumann,
  • Björn Steffen,
  • Hermann Einsele,
  • Markus Schaich,
  • Andreas Burchert,
  • Andreas Neubauer,
  • Kerstin Schäfer-Eckart,
  • Christoph Schliemann,
  • Stefan W. Krause,
  • Mathias Hänel,
  • Richard Noppeney,
  • Ulrich Kaiser,
  • Claudia D. Baldus,
  • Martin Kaufmann,
  • Carsten Müller-Tidow,
  • Uwe Platzbecker,
  • Wolfgang E. Berdel,
  • Hubert Serve,
  • Gerhard Ehninger,
  • Martin Bornhäuser,
  • Johannes Schetelig,
  • Frank Kroschinsky,
  • Christian Thiede,
  • Study Alliance Leukemia (SAL)

DOI
https://doi.org/10.1038/s41408-023-00858-y
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Tandem-duplication mutations of the UBTF gene (UBTF-TDs) coding for the upstream binding transcription factor have recently been described in pediatric patients with acute myeloid leukemia (AML) and were found to be associated with particular genetics (trisomy 8 (+8), FLT3-internal tandem duplications (FLT3-ITD), WT1-mutations) and inferior outcome. Due to limited knowledge on UBTF-TDs in adult AML, we screened 4247 newly diagnosed adult AML and higher-risk myelodysplastic syndrome (MDS) patients using high-resolution fragment analysis. UBTF-TDs were overall rare (n = 52/4247; 1.2%), but significantly enriched in younger patients (median age 41 years) and associated with MDS-related morphology as well as significantly lower hemoglobin and platelet levels. Patients with UBTF-TDs had significantly higher rates of +8 (34% vs. 9%), WT1 (52% vs. 7%) and FLT3-ITD (50% vs. 20.8%) co-mutations, whereas UBTF-TDs were mutually exclusive with several class-defining lesions such as mutant NPM1, in-frame CEBPA bZIP mutations as well as t(8;21). Based on the high-variant allele frequency found and the fact that all relapsed patients analyzed (n = 5) retained the UBTF-TD mutation, UBTF-TDs represent early clonal events and are stable over the disease course. In univariate analysis, UBTF-TDs did not represent a significant factor for overall or relapse-free survival in the entire cohort. However, in patients under 50 years of age, who represent the majority of UBTF-mutant patients, UBTF-TDs were an independent prognostic factor for inferior event-free (EFS), relapse-free (RFS) and overall survival (OS), which was confirmed by multivariable analyses including established risk factors such as age and ELN2022 genetic risk groups (EFS [HR: 2.20; 95% CI 1.52–3.17, p < 0.001], RFS [HR: 1.59; 95% CI 1.02–2.46, p = 0.039] and OS [HR: 1.64; 95% CI 1.08–2.49, p = 0.020]). In summary, UBTF-TDs appear to represent a novel class-defining lesion not only in pediatric AML but also younger adults and are associated with myelodysplasia and inferior outcome in these patients.